Nuvo Pharmaceuticals Inc
TSX:MRV
Intrinsic Value
Nuvo Pharmaceuticals, Inc. is a pharmaceutical company, which is engaged in developing innovative therapeutic pharmaceutical products. [ Read More ]
The intrinsic value of one
MRV
stock under the Base Case scenario is
5.95
CAD.
Compared to the current market price of 1.35 CAD,
Nuvo Pharmaceuticals Inc
is
Undervalued by 77%.
MRV could be a value trap.A value trap occurs when a stock looks inexpensive based on fundamental analysis but fails to reach its intrinsic valuation over time, often due to underlying issues not reflected in quantitative data.
Scrutinize beyond numbers; assess long-term potential.
Nuvo Pharmaceuticals Inc's market capitalization is 15.4m CAD.
MRV stock price is 1.35 CAD.
MRV stock price (1.35 CAD) is 77% less than its Intrinsic Value (5.95 CAD).
MRV's ROIC (Return on Invested Capital) for the past 12 months is positive and is equal to 11%.
MRV's Revenue has grown by 6% over the past 12 months.
MRV's long-term assets (127m CAD) exceed its long-term liabilties (119m CAD).
MRV's ROIC (Return on Invested Capital) has increased in the last 3 years from 9% to 11%.
MRV has positive Operating Income for the last twelve months.
MRV has positive three-year average ROE (Return on Equity): 18%. The company is efficient at transforming stockholders' equity into net income.
MRV has a very low three-year average ROIC (Return on Invested Capital): 2%. The company is not efficient at using invested capital to generate operating income.
MRV has positive Net Debt. This means that the company has more debt (86m CAD) than cash and short-term investments (31m CAD).
MRV's ROE (Return on Equity) has significantly increased in the last 3 years from -159% to 1 180%.
MRV's short-term assets (52m CAD) exceed its short-term liabilties (25m CAD).
MRV has positive Net Income for the last twelve months.
MRV's ROE (Return on Equity) for the past 12 months is very high and is equal to 1 180%.
MRV has positive Free Cash Flow for the last twelve months.
MRV has positive Gross Profit for the last twelve months.
MRV's D/E (Debt to Equity) is very high and is equal to 10.15.
MRV generates enough operating income (12m CAD) to cover interest payments on its debt (4m CAD).
MRV's Altman Z-Score is very low and is equal to -1.22.
Valuation Backtest
Nuvo Pharmaceuticals Inc
Run backtest to discover the historical profit from buying and selling
MRV
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Nuvo Pharmaceuticals Inc
Balance Sheet Decomposition
Nuvo Pharmaceuticals Inc
| Current Assets | 51.8m |
| Cash & Short-Term Investments | 31.3m |
| Receivables | 10.1m |
| Other Current Assets | 10.5m |
| Non-Current Assets | 75.4m |
| PP&E | 3.8m |
| Intangibles | 71.7m |
| Current Liabilities | 24.6m |
| Accounts Payable | 10.4m |
| Other Current Liabilities | 14.2m |
| Non-Current Liabilities | 94.2m |
| Long-Term Debt | 86.1m |
| Other Non-Current Liabilities | 8m |
Earnings Waterfall
Nuvo Pharmaceuticals Inc
|
Revenue
|
72.4m
CAD
|
|
Cost of Revenue
|
-27.4m
CAD
|
|
Gross Profit
|
45.1m
CAD
|
|
Operating Expenses
|
-32.6m
CAD
|
|
Operating Income
|
12.4m
CAD
|
|
Other Expenses
|
2.8m
CAD
|
|
Net Income
|
15.2m
CAD
|
Free Cash Flow Analysis
Nuvo Pharmaceuticals Inc
MRV Profitability Score
Profitability Due Diligence
Nuvo Pharmaceuticals Inc's profitability score is 60/100. The higher the profitability score, the more profitable the company is.
Score
Nuvo Pharmaceuticals Inc's profitability score is 60/100. The higher the profitability score, the more profitable the company is.
MRV Solvency Score
Solvency Due Diligence
Nuvo Pharmaceuticals Inc's solvency score is 25/100. The higher the solvency score, the more solvent the company is.
Score
Nuvo Pharmaceuticals Inc's solvency score is 25/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
MRV Price Targets Summary
Nuvo Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for
MRV
is 1.35 CAD
.
Shareholder Return
MRV Price
Nuvo Pharmaceuticals Inc
| Average Annual Return | 21.29% |
| Standard Deviation of Annual Returns | 89.45% |
| Max Drawdown | -85% |
| Market Capitalization | 15.4m CAD |
| Shares Outstanding | 11 400 000 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Nuvo Pharmaceuticals Inc
Country
Industry
Market Cap
Dividend Yield
Description
Nuvo Pharmaceuticals, Inc. is a pharmaceutical company, which is engaged in developing innovative therapeutic pharmaceutical products. The company is headquartered in Mississauga, Ontario and currently employs 100 full-time employees. The firm is engaged in offering diversified portfolio of commercial products. The company operates through three segments: Commercial Business, Production and Service Business and Licensing and Royalty Business. The Commercial Business segment is comprised of products commercialized by the Company in Canada. The company includes products, such as Blexten, Cambia, Suvexx and NeoVisc, as well as mature products. The Production and Service Business segment includes sale of products manufactured by the Company from its manufacturing facility in Varennes, Quebec or contracted by Miravo Ireland from its international headquarters in Dublin, Ireland, as well as service for testing, development and related quality assurance and quality control services provided by the Company. The Licensing and Royalty Business segment includes the revenue by the licensing of intellectual property and ongoing royalties from licensing agreements with partners.
Contact
IPO
Employees
Officers
The intrinsic value of one
MRV
stock under the Base Case scenario is
5.95
CAD.
Compared to the current market price of 1.35 CAD,
Nuvo Pharmaceuticals Inc
is
Undervalued by 77%.
You don't have any saved screeners yet
